TNF-α inhibitors used for the treatment of rheumatic diseases can increase the risk of frank toxoplasmosis; therefore, screening for latent T. gondii infection is strongly recommended before initiating such therapy. The gene discussed is TNF; the disease is rheumatic disorder.